Related Experiment Video
Updated: Jun 15, 2025
11:32
A Hydrogen-Deuterium Exchange Mass Spectrometry HDX-MS Platform for Investigating Peptide Biosynthetic Enzymes
Published on: May 4, 2020
8.0K
IUSTI Europe position statement on use of DoxyPEP: June 2024
Jackie Sherrard1, Deniz Gokengin2, Andrew Winter3
1Department of Sexual Health, Buckinghamshire Healthcare NHS Trust, Amersham, UK.
International Journal of STD & AIDS
|August 21, 2024
Summary
This statement guides clinicians and public health officials on reducing sexually transmitted infections (STIs), including HIV, risks. It offers strategies for effective prevention and care in the WHO European Region.
Area of Science:
- Public Health
- Infectious Diseases
- Clinical Medicine
Background:
- Sexually transmitted infections (STIs), including HIV, pose a significant public health challenge.
- Effective prevention and risk reduction strategies are crucial for vulnerable populations.
Purpose of the Study:
- To provide guidance for front-line clinical practitioners and public health authorities.
- To outline strategies for reducing the risk of acquiring STIs, including HIV.
Main Methods:
- This is a position statement, not a research study.
- It synthesizes current knowledge and expert recommendations.
Main Results:
- Key recommendations for STI/HIV risk reduction are presented.
- The statement emphasizes a multi-faceted approach to prevention.
Conclusions:
- Implementation of evidence-based strategies is essential for controlling STI/HIV transmission.
- Collaboration between clinical practitioners and public health bodies is vital.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179
01:28Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
01:30Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
00:42Cross-reactivity
31.0K
Overview
31.0K
02:43Peptide Bonds
73.9K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
73.9K
01:52Eukaryotic Transcription Inhibitors
9.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K